AOD-9604 vs Tesamorelin: Which Burns More Fat?.

Both AOD-9604 and tesamorelin leverage the growth hormone pathway for fat loss, but they take fundamentally different approaches. AOD-9604 is a modified fragment of GH (amino acids 176-191) that isolates the lipolytic activity. Tesamorelin is a GHRH analog that stimulates the pituitary to release full-spectrum endogenous GH. The choice between them involves tradeoffs between targeted simplicity and full-spectrum effects.

For a detailed side-by-side data comparison, see the full AOD-9604 vs Tesamorelin comparison page. This article focuses on the practical fat loss implications.

This needs to be stated clearly: AOD-9604 failed its Phase IIb clinical trial for weight loss. The trial showed only 1.6kg total weight loss over 12 weeks compared to placebo. Tesamorelin passed Phase III trials and earned FDA approval with 15-18% trunk fat reduction.

AOD-9604 proponents have legitimate criticisms of the trial design—it used an oral formulation (questionable peptide bioavailability), a short 12-week duration, and a general obesity population rather than targeting visceral fat specifically. But the bottom line is that one compound has clinical validation and the other does not.

Why does AOD-9604 remain popular despite this? Because its metabolic safety profile is genuinely exceptional (no glucose effects, no IGF-1 elevation), it has GRAS status in Australia, and it fits well as a component in multi-compound protocols where other compounds handle the heavy lifting and AOD provides clean, targeted lipolytic support.

If the primary goal is visceral fat reduction with clinical-grade evidence, tesamorelin is the answer. Period. No other compound in the GH pathway has Phase III data demonstrating selective visceral fat reduction. The 15-18% trunk fat reduction documented in trials is meaningful and reproducible.

Tesamorelin is also the choice when the full spectrum of GH effects is desirable: lean mass support, improved lipid profiles, enhanced recovery, and cognitive benefits (the 2019 Annals of Neurology study showed improved cognition in older adults). You get fat loss plus the broader metabolic benefits of optimized GH.

AOD-9604 is most valuable not as a standalone fat loss compound but as a component in stacking protocols. In the Recomp Stack (CJC-1295/Ipa + AOD-9604 + MOTS-C), AOD-9604 provides targeted lipolytic activity through a GH-receptor-independent pathway. CJC-1295/Ipamorelin handles GH optimization (lean mass support, recovery), and MOTS-C handles metabolic enhancement (AMPK activation, fatty acid oxidation). AOD-9604 fills a specific role: direct lipolysis without adding the complexity of another GH-axis stimulant.

Its metabolic neutrality is the key advantage here. No glucose effects, no insulin effects, no IGF-1 elevation. In a protocol that already includes GH stimulation, adding tesamorelin would create receptor competition and redundant GH-axis activity. AOD-9604 provides an orthogonal lipolytic signal.

Choose tesamorelin if: You want standalone, evidence-backed visceral fat reduction. You want the full GH spectrum (lean mass, recovery, cognition). You can access it via prescription or research supplier. You are willing to monitor IGF-1 levels.

Choose AOD-9604 if: You are building a multi-compound protocol that already includes GH stimulation (CJC-1295/Ipa). You want metabolically clean lipolysis without glucose or IGF-1 effects. You need a component piece that fits a specific role without duplicating other compounds in the stack.

Choose GLP-1 drugs if: Maximum total weight loss is the priority. Semaglutide (14.9%), tirzepatide (22.5%), and retatrutide (24.2%) all produce greater total weight loss than either AOD-9604 or tesamorelin alone. See the GLP-1 Showdown for comparison.

Tesamorelin wins as a standalone fat loss compound with clinical evidence, FDA approval, and 15-18% visceral fat reduction. AOD-9604 wins as a stack component providing clean lipolytic support without metabolic complexity. For maximum total weight loss, GLP-1 drugs outperform both. The right choice depends on whether you need a standalone solution (tesamorelin) or a targeted component for a broader protocol (AOD-9604).